Apolipoprotein E DNA methylation and late-life disease

Area of Science:

• Epigenetics
• Neurodegenerative Diseases
• Cardiovascular Health

Background:

• The apolipoprotein E (APOE) gene is implicated in dementia, Alzheimer's disease (AD), and cardiovascular disease (CVD).
• DNA methylation patterns at the APOE locus may influence disease risk.
• Understanding epigenetic modifications of APOE is crucial for disease prevention and treatment.

Purpose of the Study:

• To investigate the association between DNA methylation levels at the APOE locus and the risk of dementia, AD, and CVD.
• To determine if APOE methylation influences disease risk independently of APOE genotype.

Main Methods:

• DNA methylation levels were measured in leukocytes from 447 Swedish twins using the Illumina 450K array.
• Methylation was assessed across three distinct regions of the APOE gene: promoter, introns/exons, and 3'exon.
• Logistic regression analysis was employed to examine the relationship between methylation levels and disease odds.

Main Results:

• Increased DNA methylation in the APOE promoter region was significantly associated with higher odds of dementia and AD.
• No significant association was found between APOE methylation levels and cardiovascular disease (CVD) risk.
• The observed association between APOE promoter methylation and dementia/AD remained consistent across twin pairs and was independent of APOE genotype.

Conclusions:

• Higher DNA methylation in the APOE promoter region is a risk factor for dementia and AD.
• APOE methylation and APOE allelic variation appear to contribute independently to dementia risk.
• These findings highlight the role of epigenetics in neurodegenerative disease pathogenesis.